Teclistamab

Source: Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 25, 2025 · Captured 2026-09-09.

Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.

Context: Treatment of Relapsed or Refractory Multiple Myeloma / Treatment Options for Relapsed or Refractory Multiple Myeloma / Bispecific antibody therapy

Teclistamab is a T-cell-redirecting bispecific antibody.

Evidence (teclistamab):

In a phase I/II study (NCT03145181 and NCT04557098), teclistamab was given to 165 patients with relapsed or refractory myeloma who received at last four prior systemic treatments.[50]

Source links and citations

In a phase I/II study (NCT03145181 and NCT04557098), teclistamab was given to 165 patients with relapsed or refractory myeloma who received at last four prior systemic treatments.[50]

With a median follow-up of 14.1 months, the overall response rate was 63.0%, with a complete response rate of 39.4%. The median PFS was 11.3 months (95% CI, 8.8–17.1).[50][Level of evidence C3]

Source links and citations

In a phase I/II study (NCT03145181 and NCT04557098), teclistamab was given to 165 patients with relapsed or refractory myeloma who received at last four prior systemic treatments.[50]

Side effects included cytokine release syndrome in 72% of patients (grade 3 or 4 in only one patient) and hematologic toxicity (grade 3 or 4) in 61% of patients, including febrile neutropenia (44.8%).

In a phase I/II study (NCT03145181 and NCT04557098), teclistamab was given to 165 patients with relapsed or refractory myeloma who received at last four prior systemic treatments.[50]

Of the 165 patients, 40 patients who had received prior anti-BCMA therapy (an antibody-drug conjugate or CAR T-cell therapy) were assessed at a median follow-up of 28.0 months.[51] The overall response rate was 52.5%. A total of 47.5% of patients had a very good partial response or better, and 30.0% of patients had a complete response or better. The median duration of response was 14.8 months.[51][Level of evidence C3]

Source links and citations

Patients receiving teclistamab can be given replacement immunoglobulin G IV or subcutaneously every 2 to 4 weeks to reduce the risk of infection.[52] Replacement of immunoglobulin G may be applicable for patients receiving other bispecific antibodies.

Source links and citations

Studies cited in this source section

Source citation is not a determination that a study applies to you.

Publication references

Read the original reference and check its publication notices.

Preserved source evidence · Not medical advice